Search Result

Results for "

FASN

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Fatty Acid Synthase (FASN) (41) Akt (1) AMPK (2) Antibiotic (1) Apoptosis (12) ATP Citrate Lyase (2) Autophagy (3) Bacterial (3) Bcl-2 Family (1) Carnitine Palmitoyltransferase (CPT) (3) Caspase (2) Cytochrome P450 (1) Drug Metabolite (1) Ferroptosis (1) Fungal (1) Glutathione Peroxidase (1) Interleukin Related (1) Isotope-Labeled Compounds (1) LDLR (1) LXR (1) PI3K (3) Reactive Oxygen Species (ROS) (2) Reference Standards (5) SARS-CoV (3) Small Interfering RNA (siRNA) (3) SOD (1) Stearoyl-CoA Desaturase (SCD) (2) TNF Receptor (1)
By Research Areas:	Cancer (30) Cardiovascular Disease (1) Infection (5) Inflammation/Immunology (9) Metabolic Disease (15) Neurological Disease (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: Fatty Acid Synthase (FASN)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112829

Denifanstat 5+ Cited Publications TVB-2640; FASN-IN-2; ASC-40	Fatty Acid Synthase (FASN)	Metabolic Disease Cancer
Denifanstat (TVB-2640) is an orally active and potent Fatty Acid Synthase (FASN) inhibitor with an IC₅₀ of 0.052 μM and an EC₅₀ of 0.072 μM. Denifanstat has the potential for fatty liver disease and cancer research .

HY-12364

C75 Maximum Cited Publications 45 Publications Verification	Carnitine Palmitoyltransferase (CPT) Fatty Acid Synthase (FASN)	Cancer
C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC₅₀ of 35 μM . C75 is a potent CPT1A activator .

HY-B0218

Orlistat 30+ Cited Publications Tetrahydrolipstatin; Ro-18-0647	Fatty Acid Synthase (FASN) Apoptosis	Metabolic Disease Cancer
Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity . Anti-atherosclerotic effect .

HY-A0210

Cerulenin Maximum Cited Publications 12 Publications Verification	Fatty Acid Synthase (FASN) Fungal Apoptosis Antibiotic	Infection Metabolic Disease Cancer
Cerulenin, a potent, natural inhibitor of fatty acid synthase (FASN), is an epoxide produced by the fungus Cephalosporium caeruleus. Cerulenin inhibits topoisomerase I catalytic activity and augments SN-38-induced apoptosis. Cerulenin has antifungal and antitumor activies .

HY-120394

TVB-3166 10+ Cited Publications	Fatty Acid Synthase (FASN) Apoptosis	Cancer
TVB-3166 is an orally-available, reversible, and selective fatty acid synthase (FASN) inhibitor with IC₅₀s of 42 nM and 81 nM for biochemical FASN and cellular palmitate synthesis, respectively. TVB-3166 induces apoptosis, and inhibits in-vivo xenograft tumor growth .

HY-120062

TVB-3664 5 Publications Verification	Fatty Acid Synthase (FASN)	Cancer
TVB-3664 is an orally available, reversible, potent, selective and highly bioavailable fatty acid synthase (FASN) inhibitor, with IC₅₀ values of 18 nM and 12 nM for human and mouse cell palmitate synthesis, respectively. TVB-3664 significantly reduces tubulin palmitoylation and mRNA expression .

HY-12325

GSK2194069 5 Publications Verification	Fatty Acid Synthase (FASN)	Cancer
GSK2194069 is a potent inhibitor of β-ketoyl reductase (KR) of fatty acid synthase (FASN), with an IC₅₀ value of 7.7 nM. GSK2194069 shows specifically inhibitory effect on FAS expressing cancer cells, by acting potent efficacy on acetoacetyl-CoA, NADPH with IC₅₀ or K_i values of 4.8 nM and 5.6 nM, respectively .

HY-12648A

FASN-IN-4 tosylate 3 Publications Verification	Fatty Acid Synthase (FASN) SARS-CoV	Infection Metabolic Disease
FASN-IN-4 tosylate is a potent inhibitor of fatty acid synthase (FASN) with an IC₅₀ of 10 nM (WO2012064642A1, compound 29) . FASN-IN-4 tosylate also inhibits SARS-CoV-2 with an EC₅₀ of 18.6?nM .

HY-12364A

trans-C75 (±)-C75	Fatty Acid Synthase (FASN)	Cancer
trans-C75 ((±)-C75) is an enantiomer of C75. C75 is a synthetic fatty-acid synthase (FASN) inhibitor.

HY-N2486

Desoxyrhaponticin 1 Publications Verification	Fatty Acid Synthase (FASN) Apoptosis	Cancer
Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects.

HY-124628

IPI-9119 2 Publications Verification	Fatty Acid Synthase (FASN)	Cancer
IPI-9119 is an orally active, selective and irreversible *FASN* inhibitor with an IC₅₀ of 0.3 nM in vitro biochemical assay. IPI-9119 inhibits tumor growth of castration-resistant prostate cancer (CRPC) xenografts mouse models .

HY-N3415

Kumatakenin 1 Publications Verification	Apoptosis Autophagy Caspase Ferroptosis SARS-CoV	Neurological Disease Inflammation/Immunology Cancer
Kumatakenin is an orally active apoptosis inducer and autophagy inhibitor, with a K_d value of 2.94 μM for mouse ATG5. Kumatakenin increases the activities of caspase-3, caspase-8 and caspase-9, thereby inducing caspase-dependent apoptosis in ovarian cancer cells. Kumatakenin reduces the expression of chemokines and pro-oncogenic factors in ovarian cancer cells, and inhibits M2 macrophage polarization. Kumatakenin inactivates TRIM65 function, reduces the expression and stability of *FASN, and thus inhibits the proliferation, migration, invasion and tumor progression of esophageal cancer cells. Kumatakenin interacts with ATG5* to reduce its protein level, decrease LC3 level, and reduce the number of autophagosomes in the hippocampus. Kumatakenin binds to Eno3 to upregulate its expression, reduce the stability and expression level of IRP1 mRNA, inhibit ferroptosis, alleviate intestinal inflammation, and restore epithelial barrier function. Kumatakenin enhances the efficacy of antibiotics against pathogenic bacteria, inhibits SARS-CoV-2 replication, and reduces cytokine production. Kumatakenin is applicable to research related to ovarian cancer, esophageal cancer, depression and colitis .

HY-121250

Fasnall	Fatty Acid Synthase (FASN) Apoptosis	Cancer
Fasnall is a selective fatty acid synthase (FASN) inhibitor with an IC₅₀ of 3.71 μM. Fasnall induces apoptosis in HER2 ⁺ breast cancer cell lines. Fasnall shows potent anti-tumor activities .

HY-111551

FT113 3 Publications Verification	Fatty Acid Synthase (FASN)	Cancer
FT113 is a potent and orally active fatty acid synthase (FASN) inhibitor, with an IC₅₀ of 213 nM for full-length recombinant human FASN enzyme. In cell-based assay, FT113 blocks FASN activity in BT474 cells (IC₅₀, 90 nM). FT113 shows anti-proliferative activity, and exhibits anti-cancer activity both in vitro and in vivo .

HY-117769

GSK837149A	Fatty Acid Synthase (FASN)	Metabolic Disease
GSK837149A is a selective inhibitor of human Fatty Acid Synthase (FASN) targeting the KR domain. GSK837149A has reversible inhibition effect on *FASN* and selectivity for type I *FASN* (K_i=30 nM). GSK837149A is also a competitive inhibitor of NADPH and a non-competitive inhibitor of acetoacetyl-CoA. GSK837149A can be used for the research of obesity and breast cancer .

HY-16100

BI 99179 3 Publications Verification	Fatty Acid Synthase (FASN)	Metabolic Disease Cancer
BI 99179, a chemical probe, is a potent and selective type I fatty acid synthase (FAS) inhibitor with an IC₅₀ of 79 nM. BI 99179 is a tool compound suitable for the in vivo validation of FAS as a target for lipid metabolism related diseases. BI 99179 exhibits significant exposure (both peripheral and central) upon oral administration in rats .

HY-110354

UCM05 2 Publications Verification G28UCM	Fatty Acid Synthase (FASN) Bacterial	Infection
UCM05 (G28UCM) is a fatty acid synthase (FASN) and filamentous temperature-sensitive protein Z (Ftsz) inhibitor. UCM05 inhibits fatty acid synthesis, viral replication, and Gram-positive bacterial growth. UCM05 binds to FtsZ GTP-binding sites, inhibits GTPase activity, and disrupts Z-ring localization. UCM05 can be used for the research of HSV-1/2 infection, HIV-1 infection, and Gram-positive bacterial infections^[1][2][3].

HY-N1399

Androsin	AMPK PI3K Autophagy	Metabolic Disease Inflammation/Immunology
Androsin is an active compound isolated from Picrorhiza Kurroa Royle ex Benth. Androsin activates AMPKα/PI3K/Beclin1/LC3 signaling pathway, inhibits SREBP1c/FASN signaling pathway. Androsin can be used in research of asthma and non-alcoholic fatty liver disease (NAFLD). Androsin is orally active .

HY-B0218R

Orlistat (Standard) 30+ Cited Publications Tetrahydrolipstatin (Standard); Ro-18-0647 (Standard)	Reference Standards Fatty Acid Synthase (FASN) Apoptosis	Metabolic Disease Cancer
Orlistat (Standard) is the analytical standard of Orlistat. This product is intended for research and analytical applications. Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity . Anti-atherosclerotic effect .

HY-111777

FASN-IN-1 1 Publications Verification	Fatty Acid Synthase (FASN)	Cancer
FASN-IN-1 is a fatty acid synthase (FASN) inhibitor extracted from patent WO2015134790A1, compound 56 .

HY-N2486R

Desoxyrhaponticin (Standard)	Reference Standards Fatty Acid Synthase (FASN) Apoptosis	Cancer
Desoxyrhaponticin (Standard) is the analytical standard of Desoxyrhaponticin. This product is intended for research and analytical applications. Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects .

HY-N8144

Niga-ichigoside F1	Others	Cardiovascular Disease
Niga-ichigoside F1, an orally active ursane triterpenoid, has antihyperlipidemic and antioxidant activities. Niga-ichigoside F1 can prevent high-fat diet (HFD)-induced hepatic steatosis .

HY-W587772

Mono(2-ethyl-5-hydroxyhexyl) terephthalate MEHHTP	Drug Metabolite	Metabolic Disease
Mono (2-ethyl-5-hydroxyhexyl) terephthalate (MEHHTP), a hydroxyl metabolite of the phthalate alternative Di-2-ethylhexyl terephthalate (DEHTP), is a liver X receptor α (LXRα) agonist with a binding energy of -7.41 kcal/mol. Mono (2-ethyl-5-hydroxyhexyl) terephthalate upregulates LXRα downstream targets such as SREBP-1c and FASN and increases lipogenic enzyme activity in hepatocytes, and elevating triglyceride (TG) levels. Mono (2-ethyl-5-hydroxyhexyl) terephthalate is promising for research of nonalcoholic fatty liver disease (NAFLD) .

HY-12648

FASN-IN-4	Fatty Acid Synthase (FASN) SARS-CoV	Infection Metabolic Disease
FASN-IN-4 is a potent inhibitor of fatty acid synthase (FASN) with an IC₅₀ of 10 nM (WO2012064642A1, compound 29) . FASN-IN-4 also inhibits SARS-CoV-2 with an EC₅₀ of 18.6 nM .

HY-145809

FASN-IN-5	Fatty Acid Synthase (FASN)	Metabolic Disease Inflammation/Immunology Cancer
FASN-IN-5 (example 11), a *FASN* inhibitor, can be used for the research of TH17- or CSF1 -mediated disease or disorder such as cancer, immunological disorders, and obesity .

HY-175020

QNX-10	Fatty Acid Synthase (FASN) Apoptosis Bcl-2 Family	Cancer
QNX-10 is a fatty acid synthase (FASN) inhibitor (IC₅₀ = 0.7 μM) with anticancer activity. QNX-10 exhibits potent *FASN* inhibition and cytotoxicity against colorectal and breast cancer cells. QNX-10 induces apoptosis and cell cycle arrest in S phase by upregulating the pro-apoptotic protein Bax and downregulating the anti-apoptotic protein Bcl-xL. QNX-10 can be used to investigate anticancer therapies targeting *FASN* enzymes .

HY-176274

FASN/SCD-IN-1	Fatty Acid Synthase (FASN) Stearoyl-CoA Desaturase (SCD) Reactive Oxygen Species (ROS) Interleukin Related TNF Receptor SOD LDLR Glutathione Peroxidase	Metabolic Disease Inflammation/Immunology
FASN/SCD-IN-1 is a Silybin (HY-N0779A) derivative, an orally active inhibitor of Fatty Acid Synthase (FASN)/Stearoyl-CoA Desaturase (SCD). FASN/SCD-IN-1 has shown in vitro activity in inhibiting lipid deposition, reducing *FASN* and SCD transcriptional levels, and exhibiting antioxidant, anti-inflammatory, and anti-fibrotic activities. FASN/SCD-IN-1 has demonstrated significant hepatoprotective effects in a rat model of acute liver injury. FASN/SCD-IN-1 ameliorates the pathological features of MASH liver, including steatosis, inflammation, and fibrosis in a mouse model of myeloproliferative steatohepatitis (MASH). FASN/SCD-IN-1 can be used to study MASH .

HY-RS04755

Fasn Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Fatty Acid Synthase (FASN)	Others
Fasn Rat Pre-designed siRNA Set A contains three designed siRNAs for Fasn gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fasn Rat Pre-designed siRNA Set A Fasn Rat Pre-designed siRNA Set A

HY-RS04753

FASN Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Fatty Acid Synthase (FASN)	Others
FASN Human Pre-designed siRNA Set A contains three designed siRNAs for FASN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FASN Human Pre-designed siRNA Set A FASN Human Pre-designed siRNA Set A

HY-B0218S

Orlistat-d3 Tetrahydrolipstatin-d₃; Ro-18-0647-d₃	Isotope-Labeled Compounds Fatty Acid Synthase (FASN) Apoptosis	Metabolic Disease
Orlistat-d3 is a deuterated labeled Orlistat . Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity .?Anti-atherosclerotic?effect .

HY-U00436

FASN-IN-3	Fatty Acid Synthase (FASN)	Cancer
FASN-IN-3 is a fatty acid synthase (FASN) inhibitor extracted from patent US20170119786A1, compound 242A .

HY-12364B

(−)-C75	Fatty Acid Synthase (FASN) Carnitine Palmitoyltransferase (CPT)	Cancer
( )-C75 is a isoform of C75 (HY-12364), which is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC₅₀ of 35 μM . C75 is a potent CPT1A activator .

HY-170570

PFM046	LXR Stearoyl-CoA Desaturase (SCD) Fatty Acid Synthase (FASN)	Cancer
PFM046 is the antagonist for liver X receptor (LXR), that inhibits the activation of LXRα and LXRβ with IC₅₀ of 2.04 μM and 1.58 μM. PFM046 inhibits the expression of SCD1 and *FASN, upregulates the expression of ABCA1*, and exhibits antitumor efficacy in mouse models .

HY-155282

FASN-IN-6	Fatty Acid Synthase (FASN) Bacterial	Inflammation/Immunology
FASN-IN-6 (compound 44) is a potent fatty acid biosynthesis (FAB) inhibitor. FASN-IN-6 is an antibacterial agent with MICs of 1 μg/mL and 4 μg/mL for S. aureus ATCC 25923 and E. faecalis ATCC 29212, respectively .

HY-RS04754

Fasn Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Fatty Acid Synthase (FASN)	Others
Fasn Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fasn gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fasn Mouse Pre-designed siRNA Set A Fasn Mouse Pre-designed siRNA Set A

HY-110354R

UCM05 (Standard) G28UCM (Standard)	Reference Standards Fatty Acid Synthase (FASN) Bacterial	Infection
UCM05 (Standard) is the analytical standard of Lysipressin. This product is intended for research and analytical applications. UCM05 (G28UCM) is a fatty acid synthase (FASN) and filamentous temperature-sensitive protein Z (Ftsz) inhibitor. UCM05 inhibits fatty acid synthesis, viral replication, and Gram-positive bacterial growth. UCM05 binds to FtsZ GTP-binding sites, inhibits GTPase activity, and disrupts Z-ring localization. UCM05 can be used for the research of HSV-1/2 infection, HIV-1 infection, and Gram-positive bacterial infections ^[1][2][3].

HY-181801

FASN-IN-8	Fatty Acid Synthase (FASN) Reactive Oxygen Species (ROS) Apoptosis PI3K Akt Caspase	Cancer
FASN-IN-8 is a fatty acid synthase (FASN) inhibitor. FASN-IN-8 inhibits *FASN*-mediated de novo lipogenesis. FASN-IN-8 blocks PI3K/AKT pathway activation, inhibits cancer cells proliferation, migration and invasion. FASN-IN-8 induces apoptosis and ROS production. FASN-IN-8 can be used for the research of hepatocellular carcinoma .

HY-112522

HS79	Fatty Acid Synthase (FASN)	Cancer
HS-79 is an enantiomer of Fasnall, which is a selective fatty acid synthase (FASN) inhibitor. HS-79 is able to inhibit the incorporation of tritiated acetate into lipids with an IC₅₀ of 1.57 μM.

HY-112522A

HS80	Fatty Acid Synthase (FASN)	Cancer
HS-80 is an enantiomer of Fasnall, which is a selective fatty acid synthase (FASN) inhibitor. HS-80 is able to inhibit the incorporation of tritiated acetate into lipids with an IC₅₀ of 7.13 μM.

HY-158649

Fasnall benzenesulfonate	Fatty Acid Synthase (FASN) Apoptosis	Cancer
Fasnall benzenesulfonate is the benzenesulfonate salt form of Fasnall (HY-121250). Fasnall benzenesulfonate is the inhibitor for fatty acid synthase (FASN) with IC₅₀ of 3.7 μM. Fasnall benzenesulfonate inhibits the proliferation and induces apoptosis in breast cancer cells. Fasnall benzenesulfonate exhibits antitumor efficacy in mice .

HY-12364R

C75 (Standard)	Carnitine Palmitoyltransferase (CPT) Fatty Acid Synthase (FASN) Reference Standards	Cancer
C75 (Standard) is the analytical standard of C75. This product is intended for research and analytical applications. C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM . C75 is a potent CPT1A activator .

HY-149540

CTL-06	Fatty Acid Synthase (FASN)	Cancer
CTL-06 is an inhibitor of Fatty Acid Synthase (FASN) (IC₅₀: 3 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research .

HY-149541

CTL-12	Fatty Acid Synthase (FASN)	Cancer
CTL-12 is an inhibitor of fatty acid synthase (FASN) (IC₅₀: 2.5 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research .

HY-N1399R

Androsin (Standard)	Reference Standards AMPK PI3K Autophagy	Metabolic Disease Inflammation/Immunology
Androsin (Standard) is the analytical standard of Androsin. This product is intended for research and analytical applications. Androsin is an active compound isolated from Picrorhiza Kurroa Royle ex Benth. Androsin activates AMPKα/PI3K/Beclin1/LC3 signaling pathway, inhibits SREBP1c/FASN signaling pathway. Androsin can be used in research of asthma and non-alcoholic fatty liver disease (NAFLD). Androsin is orally active .

HY-15957

FASN-IN-7	Fatty Acid Synthase (FASN)	Cancer
FASN-IN-7 is a potent and orally active inhibitor of human Fatty Acid Synthase (FASN). FASN-IN-7 shows enzyme inhibition on full length FASN and the FASN KR domain with IC₅₀ values of 28 and 54 nM. FASN-IN-7 effectively inhibits proliferation of multiple cancer cell types. FASN-IN-7 increases malonyl-CoA levels and decreases palmitate levels in tumor tissues .

HY-N17737

Floramanoside F	Fatty Acid Synthase (FASN) Cytochrome P450	Metabolic Disease Inflammation/Immunology
Floramanoside F is a type of flavonol glycoside compound. Floramanoside F has a moderate free radical scavenging effect, with a SC₅₀ value of 25.1 μM. Floramanoside F has a relatively weak inhibitory activity on aldose reductase, with a IC₅₀ value greater than 100 μM. Floramanoside F has strong binding affinity with key target enzymes of type 1 diabetic nephropathy (T1DN) (Fasn, Cyp2e1, Cyp4a32), and can inhibit lipid accumulation and oxidative stress, thereby alleviating renal inflammation and fibrosis. Floramanoside F can be used to study type 1 diabetic nephropathy and diabetic complications .

HY-182750

ACLY-IN-3	ATP Citrate Lyase	Inflammation/Immunology
ACLY-IN-3 is an ATP-citrate lyase (ACLY) inhibitor with an IC₅₀ of 0.036 μM and a target K_d of 0.54 μM. ACLY-IN-3 interacts with the allosteric binding site of ACLY to inhibit its activity. ACLY-IN-3 exhibits excellent lipid-lowering effects and alleviates hepatic inflammation and liver fibrosis. ACLY-IN-3 can be used for the research of metabolic dysfunction-associated steatohepatitis .

HY-182751

ACLY-IN-4	ATP Citrate Lyase	Inflammation/Immunology
ACLY-IN-4 is an ATP-citrate lyase (ACLY) inhibitor with an IC₅₀ of 0.022 μM and a K_d of 0.19 μM. ACLY-IN-4 binds to the allosteric binding site of ACLY. ACLY-IN-4 exhibits hypolipidemic, anti-steatotic, insulin sensitivity-improving, anti-oxidative stress, anti-inflammatory and anti-fibrotic activities. ACLY-IN-4 alleviates hepatic steatosis, systemic insulin resistance, oxidative stress, hepatic inflammation and fibrosis. ACLY-IN-4 can be used for the research of metabolic dysfunction-associated steatohepatitis .

Cat. No.	Product Name

HY-L091

Lipid Metabolism Compound Library

969 compounds

Lipids are a fundamental class of organic molecules implicated in a wide range of biological processes, and based on this can be broadly classified into five categories: fatty acids, triacylglycerols (TAGs), phospholipids, sterol lipids and sphingolipids. Lipids play a crucial role in different metabolic pathways and cellular functions. Lipid metabolism is an important physiological process that is related to nutrient adjustment, hormone regulation, and homeostasis. Lipid metabolism dysregulation is associated with many diseases such as obesity, liver disease, aging and inflammation.

MCE offers a unique collection of 969 compounds related to lipid metabolism, which target relevant targets in the process of lipid metabolism, such as ATGL, MAGL, FAAH, acetyl-Coa Carboxylase, FASN, etc. MCE lipid metabolism compound library is a useful tool for research lipid metabolism and drug discovery of diseases related to lipid metabolism.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-A0210

Cerulenin Maximum Cited Publications 12 Publications Verification	Microorganisms Antifungal Classification of Application Fields Antibiotics Metabolic Disease Mammalian Cell Culture Disease Research Anticancer Disease Research Fields Other Antibiotics Source Classification	Fatty Acid Synthase (FASN) Fungal Apoptosis Antibiotic
Cerulenin, a potent, natural inhibitor of fatty acid synthase (FASN), is an epoxide produced by the fungus Cephalosporium caeruleus. Cerulenin inhibits topoisomerase I catalytic activity and augments SN-38-induced apoptosis. Cerulenin has antifungal and antitumor activies .

HY-N2486

Desoxyrhaponticin 1 Publications Verification	Monophenols Stilbenes Classification of Application Fields Polygonaceae Rheum rhabarbarum Linnaeus Phenols Plants Rheum tanguticum Disease Research Fields Source Classification Cancer	Fatty Acid Synthase (FASN) Apoptosis
Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects.

HY-N3415

Kumatakenin 1 Publications Verification	Flavonols Structural Classification Flavonoids Classification of Application Fields Phenols Polyphenols Myrtaceae Plants Syzygium aromaticum Disease Research Fields Source Classification Cancer	Apoptosis Autophagy Caspase Ferroptosis SARS-CoV
Kumatakenin is an orally active apoptosis inducer and autophagy inhibitor, with a K_d value of 2.94 μM for mouse ATG5. Kumatakenin increases the activities of caspase-3, caspase-8 and caspase-9, thereby inducing caspase-dependent apoptosis in ovarian cancer cells. Kumatakenin reduces the expression of chemokines and pro-oncogenic factors in ovarian cancer cells, and inhibits M2 macrophage polarization. Kumatakenin inactivates TRIM65 function, reduces the expression and stability of *FASN, and thus inhibits the proliferation, migration, invasion and tumor progression of esophageal cancer cells. Kumatakenin interacts with ATG5* to reduce its protein level, decrease LC3 level, and reduce the number of autophagosomes in the hippocampus. Kumatakenin binds to Eno3 to upregulate its expression, reduce the stability and expression level of IRP1 mRNA, inhibit ferroptosis, alleviate intestinal inflammation, and restore epithelial barrier function. Kumatakenin enhances the efficacy of antibiotics against pathogenic bacteria, inhibits SARS-CoV-2 replication, and reduces cytokine production. Kumatakenin is applicable to research related to ovarian cancer, esophageal cancer, depression and colitis .

HY-N1399

Androsin	Classification of Application Fields Ketones, Aldehydes, Acids Scrophulariaceae Plants Picrorhiza scrophulariiflora Pennell Inflammation/Immunology Disease Research Fields Source Classification	AMPK PI3K Autophagy
Androsin is an active compound isolated from Picrorhiza Kurroa Royle ex Benth. Androsin activates AMPKα/PI3K/Beclin1/LC3 signaling pathway, inhibits SREBP1c/FASN signaling pathway. Androsin can be used in research of asthma and non-alcoholic fatty liver disease (NAFLD). Androsin is orally active .

HY-N2486R

Desoxyrhaponticin (Standard)	Structural Classification Monophenols Stilbenes Polygonaceae Rheum rhabarbarum Linnaeus Phenols Plants Rheum tanguticum Source Classification	Reference Standards Fatty Acid Synthase (FASN) Apoptosis
Desoxyrhaponticin (Standard) is the analytical standard of Desoxyrhaponticin. This product is intended for research and analytical applications. Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects .

HY-N8144

Niga-ichigoside F1	Cardiovascular Disease Rhynchosia volubilis Lour. Triterpenes Classification of Application Fields Terpenoids Labiatae Plants Disease Research Fields Source Classification	Others
Niga-ichigoside F1, an orally active ursane triterpenoid, has antihyperlipidemic and antioxidant activities. Niga-ichigoside F1 can prevent high-fat diet (HFD)-induced hepatic steatosis .

HY-N1399R

Androsin (Standard)	Structural Classification Ketones, Aldehydes, Acids Scrophulariaceae Plants Picrorhiza scrophulariiflora Pennell Source Classification	Reference Standards AMPK PI3K Autophagy
Androsin (Standard) is the analytical standard of Androsin. This product is intended for research and analytical applications. Androsin is an active compound isolated from Picrorhiza Kurroa Royle ex Benth. Androsin activates AMPKα/PI3K/Beclin1/LC3 signaling pathway, inhibits SREBP1c/FASN signaling pathway. Androsin can be used in research of asthma and non-alcoholic fatty liver disease (NAFLD). Androsin is orally active .

HY-N17737

Floramanoside F	Malvaceae Structural Classification Flavonols Flavonoids Abelmoschus manihot (Linn.) Medicus Plants Source Classification	Fatty Acid Synthase (FASN) Cytochrome P450
Floramanoside F is a type of flavonol glycoside compound. Floramanoside F has a moderate free radical scavenging effect, with a SC₅₀ value of 25.1 μM. Floramanoside F has a relatively weak inhibitory activity on aldose reductase, with a IC₅₀ value greater than 100 μM. Floramanoside F has strong binding affinity with key target enzymes of type 1 diabetic nephropathy (T1DN) (Fasn, Cyp2e1, Cyp4a32), and can inhibit lipid accumulation and oxidative stress, thereby alleviating renal inflammation and fibrosis. Floramanoside F can be used to study type 1 diabetic nephropathy and diabetic complications .

Species:	Human (4)
Tag:	His (3) Strep (1) Tag Free (1) Flag (1)
Source:	HEK293 (1) Sf9 insect cells (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P701881

	FASN Protein, Human (sf9) FASN; Fatty acid synthase; Type I fatty acid synthase; [Acyl-carrier-protein] S-acetyltransferase; [Acyl-carrier-protein] S-malonyltransferase; 3-oxoacyl-[acyl-carrier-protein] synthase; 3-oxoacyl-[acyl-carrier-protein] reductase; 3-hydroxyacyl-[acyl-carrier-protein] dehydratase; Enoyl-[acyl-carrier-protein] reductase; Acyl-[acyl-carrier-protein] hydrolase	Human	Sf9 insect cells
	FASN (fatty acid synthase) is a multifunctional enzyme that is key to the de novo biosynthesis of long-chain saturated fatty acids from acetyl-CoA and malonyl-CoA using NADPH. This multifunctional protein contains seven catalytic activities and has an acyl carrier protein (ACP) domain with a binding site for the prosthetic group 4'-phosphopantetheine. FASN Protein, Human (sf9) is the recombinant human-derived FASN protein, expressed by sf9 insect cells , with tag free.

HY-P701882

	FASN Protein, Human (sf9, His) FASN; Fatty acid synthase; Type I fatty acid synthase; [Acyl-carrier-protein] S-acetyltransferase; [Acyl-carrier-protein] S-malonyltransferase; 3-oxoacyl-[acyl-carrier-protein] synthase; 3-oxoacyl-[acyl-carrier-protein] reductase; 3-hydroxyacyl-[acyl-carrier-protein] dehydratase; Enoyl-[acyl-carrier-protein] reductase; Acyl-[acyl-carrier-protein] hydrolase	Human	Sf9 insect cells
	FASN (fatty acid synthase) is a multifunctional enzyme that is key to the de novo biosynthesis of long-chain saturated fatty acids from acetyl-CoA and malonyl-CoA using NADPH. This multifunctional protein contains seven catalytic activities and has an acyl carrier protein (ACP) domain with a binding site for the prosthetic group 4'-phosphopantetheine. FASN Protein, Human (sf9, His) is the recombinant human-derived FASN protein, expressed by sf9 insect cells , with N-8*His labeled tag.

HY-P703075

	FASN Protein, Human (His, StrepⅡ, Flag) FASN; Fatty acid synthase; Type I fatty acid synthase; [Acyl-carrier-protein] S-acetyltransferase; [Acyl-carrier-protein] S-malonyltransferase; 3-oxoacyl-[acyl-carrier-protein] synthase; 3-oxoacyl-[acyl-carrier-protein] reductase; 3-hydroxyacyl-[acyl-carrier-protein] dehydratase; Enoyl-[acyl-carrier-protein] reductase; Acyl-[acyl-carrier-protein] hydrolase	Human	HEK293
	FASN (fatty acid synthase) is a multifunctional enzyme that is key to the de novo biosynthesis of long-chain saturated fatty acids from acetyl-CoA and malonyl-CoA using NADPH. This multifunctional protein contains seven catalytic activities and has an acyl carrier protein (ACP) domain with a binding site for the prosthetic group 4'-phosphopantetheine. FASN Protein, Human (His, Strep, Flag) is the recombinant human-derived FASN protein, expressed by HEK293 , with N-His, N-Strep, C-Flag labeled tag.

HY-P704038

	FASN Protein, Human (His) FASN; Fatty acid synthase; Type I fatty acid synthase; [Acyl-carrier-protein] S-acetyltransferase; [Acyl-carrier-protein] S-malonyltransferase; 3-oxoacyl-[acyl-carrier-protein] synthase; 3-oxoacyl-[acyl-carrier-protein] reductase; 3-hydroxyacyl-[acyl-carrier-protein] dehydratase; Enoyl-[acyl-carrier-protein] reductase; Acyl-[acyl-carrier-protein] hydrolase	Human	E. coli
	FASN Protein, Human (His) is the recombinant human-derived FASN protein, expressed by E. coli, with N-His tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-B0218S

Orlistat-d3
Orlistat-d3 is a deuterated labeled Orlistat . Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity .?Anti-atherosclerotic?effect .

Host:	Mouse (6) Rabbit (3)
Reactivity:	Human (9) Rat (7) Mouse (7) Monkey (2)
Application:	IHC-P (5) ICC/IF (6) IP (4) WB (7) FC (2) ELISA (1)
Isotype:	IgG (3) IgG2a (4) IgG2b (2)
Conjugation:	Non-conjugated (9)
Clonality:	Monoclonal (6) Recombinant (2)
Modification:	Unmodified (6)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86362

	Fatty Acid Synthase Antibody (YA6054) FASN; FAS; Fatty acid synthase	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	Fatty Acid Synthase Antibody (YA6054) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Fatty Acid Synthase.

HY-P80128

	Fatty Acid Synthase Antibody (YA444) 1 Publications Verification	WB, ICC/IF, IHC-P, IP, FC	Human, Mouse, Rat
	Fatty Acid Synthase Antibody (YA444) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Fatty Acid Synthase.

HY-P80668

	Fatty Acid Synthase Antibody (YA766) 2 Publications Verification FASN; FAS; Fatty acid synthase	WB, ICC/IF, IP	Human, Mouse, Rat, Monkey
	Fatty Acid Synthase Antibody (YA766) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Fatty Acid Synthase.

HY-P88401

	OXSM Antibody (YA8085) FASN2D; KASI; KS	IHC-P	Human, Mouse, Rat
	OXSM Antibody (YA8085) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to OXSM.

HY-P80668A

	Fatty Acid Synthase Antibody (YA766)(PBS only) FASN; FAS; Fatty acid synthase	WB, ICC/IF, IP	Human, Mouse, Rat, Monkey
	Fatty Acid Synthase Antibody (YA766) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Fatty Acid Synthase.

HY-P88401A

	OXSM Antibody (YA8085)(PBS only) FASN2D; KASI; KS	IHC-P	Human, Mouse, Rat
	OXSM Antibody (YA8085) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to OXSM.

HY-P88455

	MCAT Antibody (YA8139) fabD; FASN2C; MCT; MT; NET62	WB, ICC/IF	Human
	MCAT Antibody (YA8139) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to MCAT.

HY-P88455A

	MCAT Antibody (YA8139)(PBS only) fabD; FASN2C; MCT; MT; NET62	WB, ICC/IF	Human
	MCAT Antibody (YA8139) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to MCAT.

HY-P86983

	NDUFAB1 Antibody (YA6676) ACP antibody; ACPM_HUMAN antibody; Acyl carrier protein antibody; Acyl carrier protein mitochondrial antibody; CI SDAP antibody; CI-SDAP antibody; FASN 2A antibody; FASN2A antibody; MGC65095 antibody; Mitochondrial acyl carrier protein antibody; ACP antibody; ACPM_HUMAN antibody; Acyl carrier protein antibody; Acyl carrier protein mitochondrial antibody; CI SDAP antibody; CI-SDAP antibody; FASN 2A antibody; FASN2A antibody; MGC65095 antibody; Mitochondrial acyl carrier protein antibody; mitochondrial antibody; NADH dehydrogenase (ubiquinone) 1 alpha/beta subcomplex 1 8kDa antibody; NADH dehydrogenase (ubiquinone) 1 alpha/beta subcomplex 1 antibody; NADH ubiquinone oxidoreductase 9.6 kDa subunit antibody; NADH ubiquinone oxidoreductase SDAP subunit antibody; NADH-ubiquinone oxidoreductase 9.6 kDa subunit antibody; NDUFAB 1 antibody; ndufab1 antibody; SDAP antibody;	WB, IHC-P, FC	Human, Mouse, Rat
	NDUFAB1 Antibody (YA6676) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to NDUFAB1.